TCIM
MRSN

TIAA CREF Investment Management’s Mersana Therapeutics MRSN Stock Holding History

TIAA CREF Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$140K Buy
1,064
+5
+0.5% +$629 ﹤0.01% 2925
2018
Q4 		$108K Hold
1,059
– – ﹤0.01% 2955
2018
Q3 		$265K Sell
1,059
-33
-3% -$11.1K ﹤0.01% 2917
2018
Q2 		$488K Buy
1,092
+605
+124% +$266K ﹤0.01% 2791
2018
Q1 		$192K Buy
487
+166
+52% +$65.5K ﹤0.01% 2980
2017
Q4 		$132K Buy
321
+295
+1,135% +$129K ﹤0.01% 3027
2017
Q3 		$11K Buy
+26
New +$10.2K ﹤0.01% 3085

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TIAA CREF Investment Management's MRSN Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Mersana Therapeutics (MRSN) stake by 0.47% in Q1 2019, buying an estimated $629 and bringing the position to 1,064 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

TIAA CREF Investment Management first reported a position in MRSN in Q3 2017 and has held it in 7 quarters since. The position peaked at $488K in Q2 2018. 65 funds tracked by Wall St. Rank hold MRSN as of Q1 2019.

  • TIAA CREF Investment Management held 1,064 shares of Mersana Therapeutics worth $140K as of Q1 2019.
  • TIAA CREF Investment Management bought 5 Mersana Therapeutics shares in Q1 2019, an estimated $629.
  • Mersana Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2925 holding.
  • TIAA CREF Investment Management first reported a position in Mersana Therapeutics in Q3 2017 and has held it in 7 quarters since.
  • TIAA CREF Investment Management's Mersana Therapeutics position peaked at $488K in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.